Haigrui Pharma Subsidiary Receives NMPA Approval for HRS-1635 Clinical Trial Today

GateNews
According to Haigrui Pharma's announcement today (May 26), its subsidiary Chengdu Shengdi Pharma received approval from the National Medical Products Administration (NMPA) to conduct clinical trials of HRS-1635 tablets as a single agent in patients with B-cell malignancies.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments